Last reviewed · How we verify
Estracomb TTS
Estracomb TTS is a transdermal hormone replacement therapy combining estradiol and norethisterone acetate to replace declining estrogen and progestin levels in postmenopausal women.
Estracomb TTS is a transdermal hormone replacement therapy combining estradiol and norethisterone acetate to replace declining estrogen and progestin levels in postmenopausal women. Used for Menopausal vasomotor symptoms (hot flushes, night sweats), Postmenopausal hormone replacement therapy.
At a glance
| Generic name | Estracomb TTS |
|---|---|
| Sponsor | Anna Posadzy-Małaczyńska |
| Drug class | Hormone replacement therapy (HRT) |
| Target | Estrogen receptor (ER-α, ER-β) and progesterone receptor (PR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Women's Health |
| Phase | FDA-approved |
Mechanism of action
The patch delivers estradiol (a bioidentical estrogen) and norethisterone acetate (a synthetic progestin) through the skin, bypassing first-pass hepatic metabolism. This combination provides systemic hormone replacement to alleviate menopausal symptoms and protect the endometrium from unopposed estrogen stimulation.
Approved indications
- Menopausal vasomotor symptoms (hot flushes, night sweats)
- Postmenopausal hormone replacement therapy
Common side effects
- Breast tenderness
- Headache
- Nausea
- Skin irritation at patch site
- Vaginal bleeding/spotting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Estracomb TTS CI brief — competitive landscape report
- Estracomb TTS updates RSS · CI watch RSS
- Anna Posadzy-Małaczyńska portfolio CI